

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of CStone Pharmaceuticals (the “**Company**”) is pleased to announce that, Ms. Yip Betty Ho (何擘) (“**Ms. Ho**”) has been appointed as an independent non-executive Director with effect from December 30, 2024.

The biographical details of Ms. Ho are set forth below:

Ms. Ho, aged 56, has extensive experience in public companies, healthcare, merger and acquisitions, private equity across a wide range of industries. Prior to joining the Company, Ms. Ho served as chief strategy officer at DHgate Holdings Limited, a company principally engaged in cross-border e-commerce in China from April 2020 to March 2024. Ms. Ho also served as an independent non-executive director at Ezisurg Medical Co., Ltd. from May 2022 to September 2023.

Ms. Ho served as chief financial officer and director of Phoenix New Media Limited, a company listed on the New York Stock Exchange (NYSE: FENG), from October 2013 to November 2019 and from November 2017 to November 2019, respectively, preceded by her role as chief financial officer at Rock Mobile Corporation since January 2012. Ms. Ho served as chief financial officer at A8 New Media Group Limited (formerly known as A8 Digital Music Holdings Limited), a company formerly listed on The Stock Exchange of Hong Kong Limited (HKEX: 800), from July 2007 to January 2011. Ms. Ho was appointed as executive director and redesignated as non-executive director of the board of A8 New Media Group Limited from November 2007 to December 2010 and from December 2010 to May 2011, respectively.

Prior to that, Ms. Ho held various management positions in audit and investment, including chief financial officer and vice president of corporate development at Lorenzo Jewelry Limited, a wholly-owned subsidiary of LJ International, Inc. (NASDAQ: JADE), from 2001 to 2007. Before that, she was an auditor at Arthur Andersen & Co.

Ms. Ho obtained her bachelor's degree in commerce from the University of Toronto in Canada in June 1993. She also completed the Stanford Executive Leadership Program and the Stanford Director's College in the United States through a hybrid of classes in person and distance learning in May 2018. Ms. Ho has been a member of the American Institute of Certified Public Accountants since September 1997.

Ms. Ho has entered into a letter of appointment with the Company for a term of three years, and she is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the Memorandum and Articles of Association of the Company. Ms. Ho is entitled to receive a director's remuneration of HKD200,000 per annum which has been recommended by the compensation committee of the Company and approved by the Board based on, among other factors, her responsibilities, her experience and qualifications and the overall remuneration level of independent non-executive Directors.

Ms. Ho has confirmed (i) her independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (ii) that she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company; and (iii) that there are no other factors that might affect her independence at the time of her appointment.

Save as disclosed above, as far as the Board is aware and as of the date of this announcement, Ms. Ho (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (ii) does not have any relationship with any directors, senior management, or substantial or controlling shareholder of the Company; (iii) does not hold any other positions in the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, there is no other information in relation to the appointment of Ms. Ho that is required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Ms. Ho that should be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warmest welcome to Ms. Ho.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, December 30, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu, Mr. Hongbin Sun and Ms. Yip Betty Ho as independent non-executive directors.